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Multistep Carcinogenesis: Relevance to
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by J. Carl Barrett* and Roger W. Wiseman*
Carcinogenesis is a multistep process involving alterations in at least two distinct classes of genes.
Protooncogenes are activated qualitatively or quantitatively in certain tumors, and they appear to act as
positive proliferative signals for neoplastic growth. In contrast, tumor suppressor genes are normal genes
that must be inactivated or lost for tumor development. When active, tumor suppressor genes control
neoplastic growth in a negative manner. Chemicals may influence the carcinogenic process by mutational
activation of protooncogenes and/or inactivation of tumor suppressor genes. The types of genetic altera-
tions involved in these mutational events are diverse, and their dose-response curves may be varied. In
addition, chemical carcinogens may act on nonmutational processes such as the clonal expansion of
premalignant cells. The carcinogenic risk of a specific chemical is a composite of its effects on multiple
genetic and epigenetic processes.
Carcinogenesis is a Multistep
Process
It is generally accepted that chemical carcinogenesis
is a multistep process (Fig. 1). Several lines ofevidence
supporting this conclusion are listed in Table 1 and dis-
cussed in detail elsewhere (1). One of the underlying
premises of most multistep models of carcinogenesis is
that genetic and/or epigenetic alterations of multiple,
independent genes are involved. While the process of
chemical carcinogenesis can often be separated opera-
tionally into at least three stages, i.e., initiation, pro-
motion, and progression (2), it is not clear how many
genetic changes are involved in these operationally de-
fined stages.
Initiation involves the induction of an irreversibly al-
tered cell and is frequently equated with a mutational
event. This conclusion is supported by the recent find-
ings of mutational activation of ras protooncogenes in
rat mammary carcinomas, mouse skin papillomas, and
mouse hepatomas (3-7). The mechanisms of initiation
may vary, however, indifferenttissues orwithdifferent
initiators in the same tissue (4,5). Promotion is the ex-
perimentally defined process by which the initiated cell
clonally expands into a visible tumor, often a benign
lesion such as a papilloma. This process undoubtedly
involves epigenetic factors that selectively influence the
proliferation of the initiated cell. Whether genetic
mechanisms are also involved in this process is unclear.
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FIGURE 1. In this model of neoplastic development it is assumed
that the heritable alterations ofdifferent genes occur as the con-
sequence of chemically induced or spontaneous events.
For risk assessment it is important to understand how
a chemical affects all stages in the carcinogenic process.
For example, urethane (ethyl carbamate) is not a com-
plete carcinogen in mouse skin, although it is an effec-
tive initiator (8). This is presumably due to its inability
to elicit epidermal hyperplasia and to act a tumor pro-
moter (8). On the other hand, urethane is an effective
hepatic carcinogen in weanling mice, presumably be-
cause cell division in the liver during development acts
as an effective promoting stimulus (9). Phorbol esters
are active tumor promoters (10), but weak complete
carcinogens (11). This is probably due to their inability
to act as initiators (10). Thus, the lack of effective ini-
tiating or promoting activities can limit the carcinogen-
icity of a chemical in certain contexts.
The end product of tumor promotion is generally a
benign lesion or preneoplastic foci of cells. These cells
must undergo one or more additional heritable changes
during the progression to a malignant neoplasm. The
progression ofbenign tumors to malignant cancers is a
phase in carcinogenesis clearly distinct frompromotion.
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Table 1. Evidence for multistage models of carcinogenesis.
Histopathological observations of tumors reveal multiple stages
of tumor progression such as dysplasia and carcinoma in situ
Two-stage model of chemical carcinogenesis in mouse skin
shows that different chemicals affect qualitatively different
stages in the carcinogenic process
Individuals with genetic traits manifested by an early occur-
rence of cancer (e.g., familial retinoblastomas, adenomatosis
of the colon and rectum) suggest that one step in the carcino-
genic process can be a germline mutation, but additional so-
matic events are required for neoplastic development
Mathematical models based on age-specific tumor incidence
curves are consistent with four to seven independent hits re-
quired for tumors
Cell culture studies with chemical carcinogens reveal that dif-
ferent phenotypic properties of a tumor cell are acquired by
a progressive process
Cell culture studies with viral and tumor-derived oncogenes
show that neoplastic conversion of normal cells generally re-
quires multiple cooperating oncogenes. In constrast, certain
preneoplastic (immortal) cells are neoplastically transformed
by a single oncogene
Transgenic mice that carry activated protooncogenes in their
germline develop focal tumors that are apparently mono-
clonal in origin, suggesting that additional somatic events are
required for full malignant progression
This conclusion is supported by a number of observa-
tions. Malignant tumors are distinct frombenigntumors
or other preneoplastic lesions in terms of their histo-
pathological characteristics of cellular morphology, in-
vasiveness, growth, and differentiation. The stages of
promotion and progression can also be distinguished on
the basis of differential responses to certain chemical
treatments. In initiation-promotion experiments on
mouse skin, the incidence of carcinomas is not neces-
sarily proportional to the number ofpapillomas (12-17).
Telocidin, an indole alkaloid, induces more carcinomas,
but fewer papillomas, than the phorbol ester promoter
12-O-tetradecanyolphorbol-13-acetate (TPA) on 7,12-di-
methylbenz[a]anthracene (DMBA)-initiated mouse skin
(12). Mezerein is a weak promoter of epidermal papil-
lomas in SENCAR mice, but it yields a similar number
of carcinomas as the potent promoter TPA (13). Like-
wise, the free-radical-generating chemical benzoyl per-
oxide is only moderately active as a tumor promoter
but is far more active than TPA in inducing malignant
tumors (14). Finally, the anti-inflammatory steroid fluo-
cinolone acetonide inhibits DMBA-initiated, 7-bromo-
methylbenz[a]anthracene-promoted papillomas without
affecting the carcinoma incidence in treated mice (17).
These studies clearly indicate that the induction of car-
cinomas is only in part determined by the number and
nature of the benign papillomas. Tumor promoters, al-
though effective in producing multiple benign tumors
or preneoplastic foci, are not particularly effective in
influencing the progression ofthese lesions tomalignant
neoplasms in many experimental models (18,19). For
example, in the mouse skin model, phorbol ester tumor
promoters influence progression byincreasingthe num-
ber of precursor lesions (i.e., papillomas), but do not
directly induce the transition of papillomas to carcino-
mas (18,20). Treatment of benign tumors with alkyl-
ating and other mutagenic agents increases the fre-
quency and rate of malignant conversion (20,21). The
promoterTPAisineffectiveinenhancingmalignantpro-
gression, but other promoters (e.g., benzoyl peroxide
and telocidin) may effect both promotion and progres-
sion (12,14). These observations are important in un-
derstanding why treatment with complete carcinogens
is much more effective than initiation-promotion pro-
tocols for the induction of malignant tumors (22).
Thus, the evolution ofmalignant tumors from benign
lesions involves the acquisition of one or more qualita-
tive changes in the precursor cells. In fact, progression
probablyinvolvesmultiple, heritable changes. Inmouse
skin, papillomas display no histopathological evidence
of dysplasia after 10 weeks of tumor promotion with
phorbol esters (23,24); however, at later times (20-40
weeks of promotion), the papillomas show evidence of
moderate to severe dysplasia and concomitantly, aneu-
ploid tumor cells are detectable. These phenotypic
changes are also observed in the carcinomas that arise
from these papillomas (23). In chemically induced rat
hepatocarcinogenesis, multiple events are postulated to
be involved in the progression phase (25,26). In other
tissues, morphological evidence formultiple steps inthe
progressionfromdysplasticlesionstocarcinomasinsitu
and ultimately to malignant carcinomas is well estab-
lished (27).
From epidemiological studies, some human carcino-
gens have been shown to affect predominately late
stages in the carcinogenic process (28). This does not
necessarily imply that such chemicals operate similarly
to tumor promoters in two-stage experimental models.
Thechemicalmayaffect eventsintheprogressionphase
of carcinogenesis, which, as described above, are not
affected by classical promoters such as the phorbol es-
ters. Arsenic is an example of a chemical that may act
primarily as a progressor, i.e., a chemical that affects
the progression stage. Arsenic is awell-established car-
cinogen in humans (29,30), but there is little evidence
for its carcinogenicity in animals (31-33). It is inactive
as an initiator or tumor promoter in a two-stage model
ofepidermal carcinogenesis in mice (34,35). Brown and
Chu (36) have proposed that arsenic exposure affects a
late stage inthe carcinogenic process based on exposure
effects in humans. These authors have further postu-
lated that the human data are inconsistent with the
hypothesisthat arsenic acts duringthe promotion phase
ofthe carcinogenic process. This conclusion is based on
the epidemiological data that do not show reversibility
of the excess lung cancer mortality after exposure
ceases. Reversibility is one of the hallmarks of tumor
promotion (10). Based on these observations, we have
proposedthatarsenic actsspecificallyintheprogression
phase of carcinogenesis (19). This hypothesis is sup-
ported by our recent observation that arsenic is an ef-
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fective inducer ofgene amplification (37) and would ex-
plain why arsenic is ineffective as a complete carcino-
gen, initiator, or tumor promoter. Oncogene amplifi-
cation has been shown in some tumors to correlate with
the degree of neoplastic progression (38-40), and ar-
senic-induced oncogene amplification may explain the
observed increase oftumor incidence at a late stage in
humancarcinogenesis. Thesefindingsemphasizetheim-
portance of all the steps in the multistep process of
carcinogenesis. Risk assessment based only ontheprin-
ciples of initiation and promotion will not accurately
predict the hazards ofchemical carcinogens.
Carcinogenesis Involves Changes in
Two Classes of Genes:
Protooncogenes and Tumor
Suppressor Genes
Another approach to understanding the influence of
chemicals on carcinogenesis is to define the basis forthe
heritable changes in cancer cells and to elucidate the
mechanisms bywhichchemicalsaffectthesealterations.
Newunderstandings ofthe numberand types ofgenetic
changes involved in the conversion ofa normal cell into
a malignant cell are beginning to emerge. At least two
classes ofgenes have been shown to be involved in car-
cinogenesis: protooncogenes and tumor suppressor
genes (Table 2). Protooncogenes are a family ofcellular
genes with at least 30 members that appear to be in-
volved in normal cellular growth and development; ac-
tivation or inappropriate expression ofthese genes re-
sults in proliferative signals involved in neoplastic
growth (41,42). On the other hand, tumor suppressor
genes are less well defined, but the function of these
genes may also be to control cell division and possibly
differentiation (43-48). For a tumor cell to emerge,
these genes must be inactivated or lost (49,50). The
numberoftumorsuppressorgenesisunknown, butmul-
Table 2. Two classes of genes involved in carcinogenesis.
Protooncogenes
Involved in cellular growth
and differentiation
Tumor suppressor genes
Function unknown but possibly in-
volved in cellular growth and
differentiation (negative regula-
tors of cell growth?)
Family of genes exists Family of genes exists
Must be activated (quantita- Must be inactivated or lost in
tively or qualitatively) in cancers
cancers
Mutational activation by Mutational inactivation by chro-
point mutation, chromo- mosome loss, chromosome dele-
some translocation, or gene tion, point mutation, somatic re-
amplification combination or gene conversion
Little evidence for involve- Clear evidence for involvement in
ment in hereditary cancers hereditary and nonhereditary
cancers
Limited tissue specificity for Considerable tissue specificity
members of the ras gene
family
Table 3. Molecular and cytogenetic examples of mutational
changes in tumors.
Type ofgenetic change
Gene mutation
Chromosome
rearrangement
Gene amplification
Aneuploidy
Examples
Point mutation (G-*T) in codon 12
(gly--val) ofthe c-Ha-ras gene in EJ/T-
24 human bladder carcinoma
Point mutation (G-)A) in codon 12
(gly-*glu) ofthe c-Ha-ras geneinMNU-
induced mammary carcinomas
Point mutation (A-*T) in codon 664
(val->glu) ofthe neu gene in ethylnitro-
sourea-induced neuroblastomas
Philadelphia translocation [t(9;22) (q34;
ql1)] inhumanchronicmyelogenousleu-
kemia (CML) in which the c-abl pro-
tooncogene is fused to the bcr gene by
a translocation to chromosome 22q
Burkitt's lymphoma in which the c-myc
protooncogene is frequently translo-
cated to chromosome 14q, in the region
coding for the immunoglobulin heavy
chain
N-myc gene in neuroblastomas
c-myc gene in human lung carcinomas
neu gene in mammary carcinomas
+ 12 in chronic lymphocytic leukemia
+8 in ANLL, blast phase ofCML, polyps
of colon, preleukemia
+ 15 in murine T-cell leukemias
-15 in Syrian hamster tumors induced by
transfection of v-Ha-ras and v-myc
tiple genes are likely to exist, possibly with limited tis-
sue specificity (44,48).
The mechanisms of carcinogen-induced activation of
oncogenes have been elucidated, and the implications
of these findings are highly important for the risk as-
sessment of chemicals. This point can be illustrated by
three examples: (a) Carcinogen-induced point muta-
tions, resulting in activation of a ras oncogene, have
been demonstrated in carcinogenesis of skin (4), mam-
mary gland (5), and liver (6,7). In these model systems,
the data support the conclusion that these point mu-
tations are the critical changes in the initiation ofthese
tumors. These findings provide strong experimental
evidence for using the linear dose-response curves ob-
served in mutagenesis studies for carcinogen risk as-
sessment. (b) Elucidation of oncogene activation by
other genetic changes (Table 3) such as chromosome
rearrangements and gene amplification provides a the-
oretical framework for the use of these end points in
risk assessment. (c) The observations that normal cells
are notneoplasticallytransformedbyasingle oncogene,
butrather, require two or more cooperating oncogenes,
support a multistep model ofcarcinogenesis (47,51) and
have significant implications for risk assessment of
chemicals. Since at least two protooncogenes have to
beactivatedforatumorcelltoarise andtheseactivation
events may occur by different genetic mechanisms, it
is not surprising that a single carcinogen-DNA adduct
ortoxicological endpoint does notalways correlatewith
carcinogenic potency of chemicals.
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Table 4. Lines of evidence for tumor suppressor genes.
Cell hybrids
Tumorigenicity is generally suppressed in hybrids between nor-
mal and tumorigenic cells
Reexpression oftumorigenicity ofthese cell hybrids is associated
with loss of specific chromosomes
Transfer of a single, normal chromosome via microcell transfer
methods can suppress tumorigenicity of human tumor cells
Genetic predispositions to cancer
Dominantly inherited cancer susceptibilities in humans (e.g., re-
tinoblastoma and Wilms' tumor) involve a germline, hetero-
zygous mutation that becomes homozygous or hemizygous in
tumor tissue. Recently, a candidate for the retinoblastoma
gene has been cloned by several groups
Dominant inheritance of susceptibility to renal and mammary
carcinoma in the rat may involve tumor suppressor genes
More than 20 recessive-lethal mutants of Drosophilia melano-
gaster are associated with predispositions to tissue-specific
malignant neoplasms
Hybrid fish between ornamental platyfish (Xiphophorus macu-
latis) and ornamental swordtail (Xiphophorus helleri) have
increased incidence of tumors that appear to result from in-
heritance of a tumor gene (oncogene) and elimination of reg-
ulatory (tumor suppressor) gene
RFLP analyses
Analyses ofrestriction-fragment-length polymorphism ofnucleic
acid probes show that heterozygous alleles on specific chro-
mosomes frequently become homozygous in certain human
tumors
Chromosome deletions
Nonrandom chromosome deletions or losses are observed in spe-
cific types of cancers
Oncogenes have received a great deal of attention
since their discovery, and the importance of their role
in carcinogenesis has been adequately demonstrated
(41,42,51). However, considerable evidence exists that
tumor suppressor genes play an equally important role
in neoplastic development (Table 4). Recent data from
ourlaboratory have shown that in the multistep process
of chemical carcinogen-induced neoplastic transforma-
tion of Syrian hamster embryo cells in culture, the loss
ofa tumor suppressor gene function is an essential step
(Fig. 2); without the loss ofthis gene activity, multiple
oncogenes are unable to neoplastically transform the
cells (52-54).
One important distinction between oncogenes and tu-
mor suppressor genes is the differences in the mecha-
nisms bywhich carcinogens act upon these genes (Table
2). Protooncogenes have to be activated to influence
carcinogenesis. This activation event may be a quali-
tative or quantitative alteration caused by point mu-
tations, chromosome rearrangements, or gene amplifi-
cation (Table 3). In contrast, tumor suppressor genes
have tobeinactivated inorderforthetumorigenicphen-
otype tobeexpressed. Thisinactivation mayresultfrom
chromosome loss, chromosome or gene deletion, recom-
bination, gene conversion, or possibly point mutation
(49,50). The mechanisms of action and the dose re-
sponses of carcinogens in inducing the different types
of genetic changes required for the activation of pro-
tooncogenes or inactivation of tumor suppressor genes
Normal Morphological Loss of Tumor Tumorigenicits
SHE - Transformation - Immortality - Suppressive-Anchorage-
Cells / Ability Independent
\ , (sen-) (sup-) Growth
By>e ~~~~(sup'+) (tum -) (tum +)
senescence
(sen +)
FIGURE 2. Neoplastic progression of Syrian hamster cells.
may vary considerably. These multiple genetic changes,
along with the influence of tumor promoting effects in
carcinogenesis, are likely to account for the difficulties
in making simple correlations between carcinogenic ac-
tivity and any one property of a carcinogen.
Conclusions
Chemical carcinogenesis is generally a multistep pro-
cess. Not only does this process involve the stages of
initiation and promotion, but also heritable alterations
in multiple genes must occur during neoplastic pro-
gression. The genes involved in these multiple stages
appear to represent two distinct classes: protoonco-
genes, which must be activated or expressed inappro-
priately, and tumor suppressor genes, which must be
inactivated or lost. The mechanisms of activation or
inactivation ofthese genes may be quite distinct. Little
isknownaboutthedose-responses ofchemicallyinduced
genetic changes other than point mutations. The dose-
response for the carcinogenic activity response of a
chemical will be a composite of its effects on different
genetic changes. In addition, epigenetic properties of
the chemical that influence the clonal proliferation of
the initiated cells (i.e., tumor promotion) may also be
important in determining carcinogenic potency. When
chronic exposure is involved, few chemicals, ifany, will
affect only one stage in the multistep carcinogenic pro-
cess. Thus, the complex interaction ofmultiple genetic
and epigenetic factors in carcinogenesis should caution
against simplistic models ofcarcinogen risk assessment
on the basis of a single genotoxic or epigenetic mech-
anism of action.
NOTE ADDED IN PROOF: An excellent review ofthis subject, entitled
"Multistage Carcinogenesis: Implications for Risk Assessment," by
H. Yamasaki is in press in Cancer Metastasis Reviews. Important
insights concerning dose and time responses ofcomplete carcinogens
and promoters are discussed in this review, which is highly recom-
mended.
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